Amongst 203 strains of Staphylococcus aureus, MICs for CG400549 were 0.06-1.0 µg/ml, with MIC 50 and MIC 90 values each of 0.25 µg/ml. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs 0.25-2.0 µg/ml). Daptomycin MICs were 0.25-2.0 µg/ml for methicillin-susceptible and 0.25-4.0 µg/ml against methicillin-resistant strains (including vancomycin-intermedaite strains). Single-passage selections showed low resistance frequencies of CG400549 but multistep analysis showed that CG400549 yielded resistant mutants after 14-17 days in all strains tested. 
Although in the past most Staphylococcus aureus infections have been nosocomial, the past few years have witnessed worrisome emergence of community-acquired strains many of which produce Panton-Valentine leukocidin (PVL) and cause serious and life-threatening infections (4, 10, 11, 13, 18, 19) . Most community and nosocomial strains are methicillin-resistant (MRSA) and quinolone-resistant, nosocomially-acquired MRSA strains are often multiresistant (21) .
Since the first description of vancomycin intermediate S. aureus strains (VISA) in Japan, these organisms have been reported all over the world (24) . Recent lowering by the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) of the vancomycin susceptibility breakpoint from ≤4.0 µg/ml to ≤2.0 µg/ml (9) will surely lead to a much wider appreciation of the clinical importance of these strains. In 2002, the first report of vancomycin-resistant S. aureus (VRSA) producing vanA occurred (3): to date, seven VRSA strains have been reported (8,25, M. Rybak, personal communication).
It seems clear that the widespread use of vancomycin or teicoplanin in the community and hospital settings produces the selective pressure for VISA and VRSA strains: in most cases, prior glycopeptide use has been found in individual patients. The further spread of virulent community-acquired S. aureus strains (13, 20) will only exacerbate this problem. There is therefore a need for new antistaphylococcal agents with unique mechanisms of action.
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The current study investigates i) The activity of CG400549, a new experimental FabI inhibitor (Fig. 1) , compared to vancomycin, teicoplanin, linezolid, quinupristin-dalfopristin, daptomycin, amoxicillin-clavulanate, azithromycin and levofloxacin against 203 S. aureus strains by agar dilution MIC; ii) The ability of CG400549, vancomycin, linezolid, quinupristin-dalfopristin and daptomycin to select for resistance in 10 strains by single and multistep resistance selection techniques.
One hundred and three methicillin-susceptible and 100 methicillin-resistant Staphylococcus aureus were studied. Amongst MRSA strains 54 were community-acquired and 47 of these produced PVL. The MRSA strains included 5 VISA strains (including a recently isolated VISA from a patient at Hershey Medical Center which developed the VISA phenotype while the patient was on vancomycin therapy)(17) and the first 3 VRSA strains described (from Michigan, Pennsylvania and New York). Single and multistep testing used 10 S. aureus of varying phenotypes: 2 methicillin susceptible S.aureus (MSSA), 4 vancomycin-susceptible MRSA, 2 VISA and 2 VRSA strains.
CG400549 susceptibility powder was obtained from Crystalgenomics Inc., Seoul, Republic of Korea. Other antimicrobials were obtained from their respective manufacturers. Agar dilution was by CLSI methodology with added calcium for daptomycin testing (9) . Vancomycin MICs were read after a full 24 h incubation (9).
For single step resistance studies, two methicillin susceptible S.aureus and 8 MRSA (including 2 VRSA, 2 VISA) were tested as previously described (6). Because colonies obtained at these MICs often occurred on a background of confluent growth, retesting by agar dilution MIC was performed. To ensure reproducibility and reliability of results, resistance in single step studies was defined as MIC >4 times higher than the parent.
In multistep resistance selection tests, 10 S. aureus strains including 8 MRSA (2 VRSA, 2 VISA) and 2 methicillin susceptible S.aureus were examined. Serial passages were performed daily for each strain in subinhibitory concentrations of all antimicrobials. Methods were those described previously (6). Identity of obtained mutants and their respective parents was confirmed by pulsed-field gel electrophoresis at the end of the study using a CHEF DR III apparatus (Bio-Rad, Hercules, CA)(2).
Amongst 203 methicillin-susceptible and -resistant strains of S. aureus, including strains with reduced susceptibility to vancomycin and teicoplanin, MICs for CG400549 were all between 0.06 and 1.0 µg/ml, with
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on October 2, 2017 by guest http://aac.asm.org/ Downloaded from dalfopristin (MICs between 0.25 and 2.0 µg/ml for both compounds). Daptomycin MICs ranged between 0.25 and 2.0 µg/ml for methicillin-susceptible and 0.25-4.0 µg/ml against methicillin-resistant strains. When vancomycin non-susceptible strains were excluded, the highest daptomycin MIC was 1.0 µgMethicillin-susceptible strains were amoxicillin/clavulanate-susceptible and resistance to levofloxacin and azithromycin was found (Table 1) .
Results of single step studies are presented in Table 2 . Parental MICs (µg/ml) were as follows: CG 400549, 0.125-1; vancomycin, 1->64; linezolid, 0.5-2; quinupristin-dalfopristin, 0.5-1; daptomycin, 0.5-8. Results of multistep selection studies are presented in Table 3 . MICs of parent strains (µg/ml) were: CG400549, 0.125-1; vancomycin, 2->64; linezolid, 1-4; quinupristin-dalfopristin, 0.125-0.5; daptomycin, 1-16.
As can be seen, CG400549 selected for resistant mutants in all 10 strains after 14-17 days (parents 0.125-1 µg/ml, mutants 2->64 µg/ml). By comparison, daptomycin selected mutants in 8 of the 10 strains after 14-24 days (parents 1 µg/ml, mutants 8 µg/ml). Linezolid selected for resistant mutants in 7 of 10 strains after 15-48 days (parents 1-4 µg/ml, mutants 8-32 µg/ml). Quinupristin/dalfopristin selected for resistant mutants in all 10 strains tested after 14-23 days (parents 0.125-0.5 µg/ml, mutants 1-4 µg/ml). quinupristin/dalfopristin) had daptomycin MICs 2-3 dilutions lower than that of the parent and 9 mutants (3 CG400549, 2 daptomycin, and 4 quinupristin/dalfopristin) had vancomycin MICs 2->5 dilutions lower than parent strains (Table 3) . Additionally, 2 CG400549 mutants and 2 daptomycin mutants had MICs 2 dilutions lower after 10 daily subcultures on antibiotic-free media as compared to the mutant MICs before the subcultures (Table 3 ). All resistant clones were identical to parents by pulse field analysis.
Previous studies have demonstrated elevated CG400549 MICs in FabI over-expressed S. aureus strains;
animal studies showed promising results and the drug was safe up to 1 g/kg of subcutaneous or oral use (16).
CG400549 MIC 90 values were all 0.5 µg/ml against 1 VISA, 215 MRSA and 41 coagulase-negative methicillinresistant staphylococci (15) . CG400549 was bactericidal at 8 x MIC after 24 h, with a PAE against MRSA of 1 h. Development of resistance to this drug in S. aureus was rare, with a frequency of 2.1 x 10 -8 (14) .
Results of single step studies showed low resistance frequencies of CG400549, either comparable to or lower than those of other compounds tested, including against strains non-susceptible to vancomycin. However, multistep resistance selection studies showed that in all 10 strains CG 400549 yielded resistant mutants with
MICs of 2->64 µg/ml. The clinical significance of low yield of resistant mutants by CG400549 in single step testing as compared with high yield of resistant mutants by multistep remains to be elucidated.
Fourteen detected mutants selected by vancomycin or daptomycin showed unstable resistance phenotypes (Table 3) . This phenomenon has been described in previous studies. Boyle-Vavra et al. This study was supported by a grant from Crystalgenomics Inc., Seoul, Republic of Korea. 

